{
    "2019-09-04": [
        [
            {
                "time": "",
                "original_text": "长春高新：拟投不超6200万元，获5%“利多卡因透皮贴片”中国大陆销售权等",
                "features": {
                    "keywords": [
                        "长春高新",
                        "利多卡因透皮贴片",
                        "销售权",
                        "投资"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "长春高新：拟与美国“Amesino”共同设立“抗体平台合资公司”",
                "features": {
                    "keywords": [
                        "长春高新",
                        "Amesino",
                        "抗体平台",
                        "合资公司"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "长春高新(000661.SZ)拟不超6200万元获得5%利多卡因透皮贴片在中国大陆区域的销售权及全球区域的生产权",
                "features": {
                    "keywords": [
                        "长春高新",
                        "利多卡因透皮贴片",
                        "销售权",
                        "生产权",
                        "国际合作"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【东吴医药】医药生物行业2019H1业绩总结：行业增速放缓，龙头引领增长，聚焦创新药产业链、创新生物制品、医疗服务等景气细分赛道",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业增速",
                        "创新药",
                        "生物制品",
                        "医疗服务"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}